1. Home

Featured Tests

OmniSeq®

A complete testing portfolio powered by precision medicine.

OmniSeq Advance Assay

 

IntelliGEN® Myeloid

NGS assay covering 50 genes associated with myeloid malignancies

IntelliGEN® Myeloid

 

PIK3CA Mutation Analysis

FDA approved companion diagnostic for advanced breast cancer

PIK3CA Mutation Analysis

 

Resolution ctDx LungTM Assay

ctDNA liquid biopsy assay that targets actionable, somatic SNVs, indels, fusions, and copy number variants in 23 genes in NSCLC

Resolution ctDx Lung Assay

News & Announcements

PD-L1 (22C3) IHC in TNBC

Integrated Oncology now expands the offering of the PD-L1 IHC (22C3) pharmDx assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples.  This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with KEYTRUDA®(pembrolizumab) in combination with chemotherapy. 

Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences, Foundation Medicine, Illumina, LabCorp, QIAGEN, Roche Diagnostics, and Thermo Fisher Scientific.

HLA Today

Improve patient outcomes with HLA Today sponsored testing program.  Offered by the National Marrow Donor Program®/Be the Match® in partnership with Integrated Oncology/LabCorp®

Resolution ctDx Lung Assay

ctDNA liquid biopsy assay that evaluates 23 actionable genes, genes with driver mutations targeted by a specific FDA-approved therapy or therapies now in clinical trials, for patients with advanced NSCLC. 

FDA approved, companion diagnostic, QIAGEN therascreen® PIK3CA mutation analysis assay for breast cancer is now available

The assay is intended to aid clinicians in identifying PIK3CA-mutated advanced or metastatic breast cancer patients who may be eligible for treatment with PIQRAY® (alpelisib). [Press Release]

LabCorp announces new agreements with UnitedHealthcare and Aetna

LabCorp is now in-network for all major national plans.

FDA approved, companion diagnostic, QIAGEN therascreen® FGFR mutation analysis assay for locally advanced or metastatic urothelial carcinoma, is now available

The assay is used to assess the eligibility of patients for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech, Inc. (Janssen).  [Press Release]

NTRK Gene Fusions

TRK fusion proteins are oncogenic drivers that occur in a broad range of tumors across adult and pediatric cancers. Genomic profiling using either the OmniSeq AdvanceSM assay or the OmniSeq Comprehensive® assay can identify actionable NTRK gene fusions for TRK inhibitor treatment selection.

OmniSeq Advance Assay OmniSeq Comprehensive Assay

PD-L1 (SP142) IHC in TNBC

Integrated Oncology now expands the offering of the VENTANA PD-L1 (SP142) IHC assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples.  This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with TECENTRIQ® (atezolizumab) plus chemotherapy.